{"filing":{"accession_number":"0001193125-26-349198","cik":"0001426800","ticker":"ASMB","company_name":"ASSEMBLY BIOSCIENCES, INC.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"asmb-20260813.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1426800/000119312526349198/asmb-20260813.htm"},"events":[{"id":27597,"run_id":25163,"accession_number":"0001193125-26-349198","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Assembly Biosciences issued a press release on August 13, 2026 announcing financial results for the quarter ended June 30, 2026, including revenue of $13.4 million, R\u0026D expenses of $14.9 million, and a net loss of $3.9 million ($0.20 per share). The filing includes condensed consolidated balance sheets and statements of operations with comparative periods, which is the standard format for quarterly earnings disclosures under Item 2.02.","company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29187,"accession_number":"0001193125-26-349198","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Assembly Biosciences issued a press release on August 13, 2026 announcing financial results for the quarter ended June 30, 2026, including revenue of $13.4 million, R\u0026D expenses of $14.9 million, and a net loss of $3.9 million ($0.20 per share). The filing includes condensed consolidated balance sheets and statements of operations with comparative periods, which is the standard format for quarterly earnings disclosures under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:02:36.153812+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29187,"accession_number":"0001193125-26-349198","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Assembly Biosciences issued a press release on August 13, 2026 announcing financial results for the quarter ended June 30, 2026, including revenue of $13.4 million, R\u0026D expenses of $14.9 million, and a net loss of $3.9 million ($0.20 per share). The filing includes condensed consolidated balance sheets and statements of operations with comparative periods, which is the standard format for quarterly earnings disclosures under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:02:36.153812+00:00","company_name":"ASSEMBLY BIOSCIENCES, INC.","ticker":"ASMB","filing_date":"2026-08-13"}]}